22 assets in Synovial Sarcoma

Therapeutic assets addressing Synovial Sarcoma, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Cyclophosphamide Synovial Sarcoma	Zelluna Immunotherapy AS	P2	BB (66)
Pembrolizumab Synovial Sarcoma	Valo Therapeutics Oy	P2	B (63)
Fludarabine Synovial Sarcoma	Zelluna Immunotherapy AS	P1/2	CCC (52)
cd146/her2 car-t cells Synovial Sarcoma	Essen Biotech	P1/2	CCC (48)
Decitabine Synovial Sarcoma	Roswell Park Cancer Institute	P1/2	CCC (48)
Hbi 0201-Eso Tcrt Synovial Sarcoma	Hadassah Medical Organization	P1/2	CCC (48)
Olaparib Synovial Sarcoma	Fundación de investigación HM	P1/2	CCC (48)
Oxodotreotide Synovial Sarcoma	Fundación de investigación HM	P1/2	CCC (48)
Zoledronate Synovial Sarcoma	University of Florida	P1/2	CC (47)
Autologous Genetically Modified Mage-A4ᶜ¹º³²T Cells Synovial Sarcoma	USWM CT, LLC	P1	CC (43)
ima203 Synovial Sarcoma	Immatics US, Inc.	P1	CC (43)
MDG1015 Synovial Sarcoma	Medigene AG	P1	CC (43)
Mrna-4203 Synovial Sarcoma	Immatics US, Inc.	P1	CC (43)
Pcna Inhibitor Aoh1996 Synovial Sarcoma	City of Hope Medical Center	P1	CC (43)
Pepticrad-1 Synovial Sarcoma	Valo Therapeutics Oy	P1	CC (43)
Second Generation 4-1Bbζ B7H3-Egfrt-Dhfr Synovial Sarcoma	Seattle Children's Hospital	P1	CC (43)
Second Generation 4-1Bbζ Egfr806-Egfrt Synovial Sarcoma	Seattle Children's Hospital	P1	CC (43)
Second Generation 4-1Bbζ Egfr806-Egfrt And A Second Generation 4 1Bbζ Cd19-Her2Tg Synovial Sarcoma	Seattle Children's Hospital	P1	CC (43)
Sendegobresib Synovial Sarcoma	C4 Therapeutics, Inc.	P1	CC (43)
Tbi-1301 Synovial Sarcoma	University Health Network, Toronto	P1	CC (43)
Zi-Ma4-1 Synovial Sarcoma	Zelluna Immunotherapy AS	P1	CC (43)